MktsMarkets

Cytokinetics, Incorporated
NASDAQ: CYTKKey statistics
CYTK News
Stories mentioning CYTK from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 19,355 | 17,755 | 1,936 | 66,769 | 1,579 | 16,927 | 463.00 | 249.00 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 95,525 | 105,977 | 99,233 | 112,554 | 98,262 | 93,629 | 84,612 | 79,597 |
| Sales General & Admin | 104,896 | 57,369 | ||||||
| Total Operating Expenses | 202,973 | 196,121 | 168,691 | 178,275 | 157,210 | 155,967 | 141,264 | 130,421 |
| Operating Income (Loss) | (183,618) | (178,366) | (166,755) | (111,506) | (155,631) | (139,040) | (140,801) | (130,172) |
| Interest Income | ||||||||
| Interest Expense | 11,353 | 11,084 | 8,938 | 8,928 | 12,732 | |||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (206,031) | (183,031) | (306,178) | (134,370) | (161,376) | (150,020) | (160,545) | (143,318) |
| Earnings Per Share (Basic) | (1.67) | (1,525) | (2.55) | (1.12) | (1.36) | (1,339) | (1.36) | (1.31) |
| Earnings Per Share (Diluted) | (1.67) | (1,525) | (2.55) | (1.12) | (1.36) | (1,339) | (1.36) | (1.31) |
| Weighted Average Shares Outstanding (Basic) | 123.00 | 120.00 | 120.00 | 119.00 | 118.00 | 112.00 | 118.00 | 109.00 |
| Weighted Average Shares Outstanding (Diluted) | 123.00 | 120.00 | 120.00 | 119.00 | 118.00 | 112.00 | 118.00 | 109.00 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About CYTK
Cytokinetics, Incorporated (NASDAQ: CYTK) is a stock listed on the Nasdaq Stock Market under the ticker symbol CYTK. It last traded at $51.32 (Nov 18, 2026, 4:00 PM ET), down 0.6% on the day. That gives Cytokinetics a market capitalisation of $7.2B.
Over the past 52 weeks CYTK has traded between $51.37 and $88.31.
Revenue for the quarter ended Mar 31, 2026 was $19.4M; a net loss of $206.0M. Revenue was up 1126% from $1.6M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $19.4M | -$206.0M | -1064.5% |
| Dec 31, 2025 | $17.8M | -$183.0M | -1030.9% |
| Sep 30, 2025 | $1.9M | -$306.2M | -15815.0% |
| Jun 30, 2025 | $66.8M | -$134.4M | -201.2% |
From Cytokinetics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…